PTCT vs. CORT, XENE, FOLD, SMMT, IDYA, ARWR, DYN, RNA, MOR, and MRVI
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Corcept Therapeutics (CORT), Xenon Pharmaceuticals (XENE), Amicus Therapeutics (FOLD), Summit Therapeutics (SMMT), IDEAYA Biosciences (IDYA), Arrowhead Pharmaceuticals (ARWR), Dyne Therapeutics (DYN), Avidity Biosciences (RNA), MorphoSys (MOR), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry.
PTC Therapeutics (NASDAQ:PTCT) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
PTC Therapeutics currently has a consensus target price of $35.67, suggesting a potential downside of 2.20%. Corcept Therapeutics has a consensus target price of $40.10, suggesting a potential upside of 26.86%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than PTC Therapeutics.
PTC Therapeutics received 17 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 70.62% of users gave Corcept Therapeutics an outperform vote while only 61.83% of users gave PTC Therapeutics an outperform vote.
In the previous week, PTC Therapeutics had 13 more articles in the media than Corcept Therapeutics. MarketBeat recorded 25 mentions for PTC Therapeutics and 12 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.03 beat PTC Therapeutics' score of 0.50 indicating that Corcept Therapeutics is being referred to more favorably in the news media.
PTC Therapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.
93.6% of Corcept Therapeutics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Corcept Therapeutics has a net margin of 22.38% compared to PTC Therapeutics' net margin of -62.45%. Corcept Therapeutics' return on equity of 24.19% beat PTC Therapeutics' return on equity.
Corcept Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Corcept Therapeutics beats PTC Therapeutics on 13 of the 17 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
